Display options
Cite
Pothen L, Balligand JL. Legacy in Cardiovascular Risk Factors Control: From Theory to Future Therapeutic Strategies?. Antioxidants (Basel). 2021;10(11)doi: 10.3390/antiox10111849.
Pothen, L., & Balligand, J. L. (2021). Legacy in Cardiovascular Risk Factors Control: From Theory to Future Therapeutic Strategies?. Antioxidants (Basel, Switzerland), 10(11), . https://doi.org/10.3390/antiox10111849
Pothen, Lucie, and Balligand, Jean-Luc. "Legacy in Cardiovascular Risk Factors Control: From Theory to Future Therapeutic Strategies?." Antioxidants (Basel, Switzerland) vol. 10,11 (2021). doi: https://doi.org/10.3390/antiox10111849
Pothen L, Balligand JL. Legacy in Cardiovascular Risk Factors Control: From Theory to Future Therapeutic Strategies?. Antioxidants (Basel). 2021 Nov 22;10(11). doi: 10.3390/antiox10111849. PMID: 34829720; PMCID: PMC8614708.
Copy Download .nbib Format: NLM
Share it on

Antioxidants (Basel). 2021 Nov 22;10(11). doi: 10.3390/antiox10111849.

Legacy in Cardiovascular Risk Factors Control: From Theory to Future Therapeutic Strategies?.

Antioxidants (Basel, Switzerland)

Lucie Pothen, Jean-Luc Balligand

Affiliations

  1. Institute of Experimental and Clinical Research (IREC), Pharmacology and Therapeutics (FATH), Cliniques Universitaires St-Luc and Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.

PMID: 34829720 PMCID: PMC8614708 DOI: 10.3390/antiox10111849

Abstract

In medicine, a legacy effect is defined as the sustained beneficial effect of a given treatment on disease outcomes, even after cessation of the intervention. Initially described in optimized control of diabetes, it was also observed in clinical trials exploring intensification strategies for other cardiovascular risk factors, such as hypertension or hypercholesterolemia. Mechanisms of legacy were particularly deciphered in diabetes, leading to the concept of metabolic memory. In a more discreet manner, other memory phenomena were also described in preclinical studies that demonstrated long-lasting deleterious effects of lipids or angiotensin II on vascular wall components. Interestingly, epigenetic changes and reactive oxygen species (ROS) appear to be common features of "memory" of the vascular wall.

Keywords: ROS; angiotensin II; diabetes; hypercholesterolemia; hypertension; legacy effect; metabolic memory; oxLDL

References

  1. J Hypertens. 2015 Nov;33(11):2331-7 - PubMed
  2. N Engl J Med. 2005 Dec 22;353(25):2643-53 - PubMed
  3. Diabetes Care. 2011 May;34 Suppl 2:S297-303 - PubMed
  4. Arterioscler Thromb Vasc Biol. 2014 Aug;34(8):1731-8 - PubMed
  5. N Engl J Med. 2008 Jun 12;358(24):2545-59 - PubMed
  6. Diabetes. 2021 Feb;70(2):328-337 - PubMed
  7. Trends Endocrinol Metab. 2018 Sep;29(9):602-605 - PubMed
  8. Pharmacol Rev. 2015 Oct;67(4):754-819 - PubMed
  9. N Engl J Med. 2009 Jan 8;360(2):129-39 - PubMed
  10. Lancet. 2002 Apr 20;359(9315):1379-87 - PubMed
  11. Diabetes Care. 2016 May;39(5):701-8 - PubMed
  12. Diabetes Obes Metab. 2018 Jun;20(6):1337-1341 - PubMed
  13. N Engl J Med. 1993 Sep 30;329(14):977-86 - PubMed
  14. Eur Heart J. 2011 Oct;32(20):2525-32 - PubMed
  15. Front Immunol. 2019 Jan 23;10:13 - PubMed
  16. J Mol Med (Berl). 2020 Jun;98(6):819-831 - PubMed
  17. Antioxid Redox Signal. 2021 May 20;34(15):1165-1199 - PubMed
  18. Clin Exp Pharmacol Physiol. 2011 Jul;38(7):451-9 - PubMed
  19. N Engl J Med. 1998 Nov 5;339(19):1349-57 - PubMed
  20. N Engl J Med. 2003 Feb 13;348(7):583-92 - PubMed
  21. Circulation. 2016 Mar 15;133(11):1073-80 - PubMed
  22. Diabetes. 2009 May;58(5):1229-36 - PubMed
  23. Lancet. 2018 Sep 29;392(10153):1127-1137 - PubMed
  24. Invest Ophthalmol Vis Sci. 1993 May;34(6):2092-6 - PubMed
  25. Cardiovasc Diabetol. 2020 Mar 5;19(1):28 - PubMed
  26. J Am Heart Assoc. 2014;3(2):e000810 - PubMed
  27. Diabetes. 2014 May;63(5):1748-62 - PubMed
  28. J Hum Hypertens. 2020 Apr;34(4):261-270 - PubMed
  29. Lancet. 1998 Sep 12;352(9131):837-53 - PubMed
  30. N Engl J Med. 2010 Apr 29;362(17):1563-74 - PubMed
  31. Eur Heart J. 2021 Aug 17;42(31):2995-3007 - PubMed
  32. N Engl J Med. 2016 May 26;374(21):2021-31 - PubMed
  33. Lancet. 2002 Mar 23;359(9311):995-1003 - PubMed
  34. N Engl J Med. 2019 Jun 6;380(23):2215-2224 - PubMed
  35. Front Endocrinol (Lausanne). 2018 Jan 17;9:2 - PubMed
  36. Free Radic Biol Med. 2013 Dec;65:897-907 - PubMed
  37. Diabetes Care. 2019 Mar;42(3):416-426 - PubMed
  38. JAMA. 1991 Jun 26;265(24):3255-64 - PubMed
  39. Kidney Int. 2018 Jun;93(6):1330-1343 - PubMed
  40. Lancet. 2005 Sep 10-16;366(9489):895-906 - PubMed
  41. J Mol Cell Cardiol. 2020 Sep;146:121-132 - PubMed
  42. N Engl J Med. 2016 May 26;374(21):2009-20 - PubMed
  43. Life Sci. 2016 Mar 15;149:18-24 - PubMed
  44. J Clin Lipidol. 2019 Jan - Feb;13(1):148-155 - PubMed
  45. Proc Natl Acad Sci U S A. 1990 Jan;87(1):404-8 - PubMed
  46. N Engl J Med. 2011 Mar 10;364(10):907-17 - PubMed
  47. Arterioscler Thromb Vasc Biol. 2021 Feb;41(2):698-710 - PubMed
  48. Diabetologia. 2017 Nov;60(11):2183-2191 - PubMed
  49. Circ Res. 2010 Oct 29;107(9):1058-70 - PubMed
  50. Biochem Cell Biol. 2020 Feb;98(1):12-22 - PubMed
  51. Hypertens Res. 2012 Mar;35(3):334-40 - PubMed
  52. N Engl J Med. 2008 Oct 9;359(15):1565-76 - PubMed
  53. N Engl J Med. 2015 Jun 4;372(23):2197-206 - PubMed
  54. J Clin Hypertens (Greenwich). 2012 Jan;14(1):20-31 - PubMed
  55. Front Immunol. 2019 Jan 22;9:3155 - PubMed
  56. J Am Soc Nephrol. 2016 Jul;27(7):2092-108 - PubMed
  57. Diabetes Obes Metab. 2016 Jun;18(6):598-606 - PubMed
  58. Diabetes. 2013 Jun;62(6):1800-7 - PubMed
  59. Front Physiol. 2014 Oct 29;5:396 - PubMed
  60. Lancet. 2003 Apr 5;361(9364):1149-58 - PubMed
  61. J Clin Hypertens (Greenwich). 2013 Aug;15(8):542-54 - PubMed
  62. Diabetes. 1987 Jul;36(7):808-12 - PubMed
  63. J Hypertens. 2009 Aug;27(8):1509-20 - PubMed
  64. JAMA. 2011 Dec 21;306(23):2588-93 - PubMed
  65. Am J Pathol. 2011 May;178(5):2205-14 - PubMed
  66. JAMA. 2002 Dec 18;288(23):2998-3007 - PubMed
  67. Physiol Rev. 2018 Jul 1;98(3):1627-1738 - PubMed
  68. Nat Rev Nephrol. 2019 Jun;15(6):327-345 - PubMed
  69. Atherosclerosis. 2016 Nov;254:228-236 - PubMed
  70. Hypertension. 2010 Dec;56(6):1060-8 - PubMed
  71. N Engl J Med. 1995 Nov 16;333(20):1301-7 - PubMed
  72. J Mol Endocrinol. 2019 Nov;63(4):R103-R115 - PubMed
  73. Int J Mol Sci. 2021 May 10;22(9): - PubMed
  74. N Engl J Med. 2008 Oct 9;359(15):1577-89 - PubMed
  75. Diabetologia. 2017 Nov;60(11):2192-2199 - PubMed
  76. N Engl J Med. 2008 Jun 12;358(24):2560-72 - PubMed
  77. Circ Res. 2012 Jul 20;111(3):278-89 - PubMed
  78. N Engl J Med. 2014 Oct 9;371(15):1392-406 - PubMed
  79. Diabetes. 2005 Jun;54(6):1615-25 - PubMed
  80. BMJ. 1998 Sep 12;317(7160):703-13 - PubMed
  81. Arterioscler Thromb Vasc Biol. 2011 Sep;31(9):2125-35 - PubMed
  82. Ther Adv Cardiovasc Dis. 2016 Jun;10(3):151-61 - PubMed
  83. Diabetologia. 2015 Mar;58(3):443-55 - PubMed
  84. BMJ Open. 2018 Oct 4;8(9):e020584 - PubMed

Publication Types

Grant support